CCN2 and melanoma: CTGF was found to be overexpressed in mammary tumors [26], [35], melanomas [36], pancreatic cancers [37], sarcomas including chondrosarcomas [38], [39]; while an inverse correlation has been reported between the malignant phenotype and the level of CTGF expression in fibroblasts and endothelial cell tumors [40].